Volume 125, Issue 3, Pages (September 2003)

Slides:



Advertisements
Similar presentations
Genetic testing for high-risk colon cancer patients1 William M. Grady Gastroenterology Volume 124, Issue 6, Pages (May 2003) DOI: /S (03)
Advertisements

Overview and pathogenesis of celiac disease Martin F. Kagnoff Gastroenterology Volume 128, Issue 4, Pages S10-S18 (April 2005) DOI: /j.gastro
Celiac Disease Genetics: Current Concepts and Practical Applications Ludvig M. Sollid, Benedicte A. Lie Clinical Gastroenterology and Hepatology Volume.
Serum immunoglobulin a from patients with celiac disease inhibits human T84 intestinal crypt epithelial cell differentiation Tuula Halttunen, Markku Mäki.
Volume 130, Issue 2, Pages (February 2006)
Volume 132, Issue 3, Pages (March 2007)
Volume 124, Issue 5, Pages (May 2003)
Small Intestinal CD4+ T-Cell Lymphoma Is a Heterogenous Entity With Common Pathology Features  Georgia Malamut, Bertrand Meresse, Sophie Kaltenbach, Coralie.
Accuracy of Testing for Antibodies to Synthetic Gliadin–Related Peptides in Celiac Disease  Emilia Sugai, Horacio Vázquez, Fabio Nachman, María Laura.
Volume 151, Issue 4, Pages (October 2016)
Volume 118, Issue 6, Pages (June 2000)
Volume 116, Issue 5, Pages (May 1999)
Small Intestinal CD4+ T-Cell Lymphoma Is a Heterogenous Entity With Common Pathology Features  Georgia Malamut, Bertrand Meresse, Sophie Kaltenbach, Coralie.
Volume 128, Issue 2, Pages (February 2005)
Volume 143, Issue 3, Pages e4 (September 2012)
Volume 134, Issue 5, Pages (May 2008)
Enzyme-modified wheat gliadin activates T cells in celiac disease
Nicholas S. Coleman, Stephen Foley, Simon P
Volume 143, Issue 6, Pages e2 (December 2012)
Volume 131, Issue 2, Pages (August 2006)
Volume 134, Issue 4, Pages (April 2008)
Volume 133, Issue 4, Pages (October 2007)
Unexpected Role of Surface Transglutaminase Type II in Celiac Disease
Volume 127, Issue 3, Pages (September 2004)
Gliadin Does Not Induce Mucosal Inflammation or Basophil Activation in Patients With Nonceliac Gluten Sensitivity  Cristina Bucci, Fabiana Zingone, Ilaria.
Volume 136, Issue 1, Pages (January 2009)
Volume 124, Issue 5, Pages (May 2003)
Enteroinvasive bacteria alter barrier and transport properties of human intestinal epithelium: Role of iNOS and COX-2  Silvia Resta–Lenert, Kim E. Barrett 
Interleukin 15 mediates epithelial changes in celiac disease
Association Between Ipilimumab and Celiac Disease
Volume 133, Issue 3, Pages (September 2007)
Mucosal Healing in Patients With Celiac Disease and Outcomes of Pregnancy: A Nationwide Population-Based Study  Benjamin Lebwohl, Olof Stephansson, Peter.
Video Capsule Endoscopy and Histology for Small-Bowel Mucosa Evaluation: A Comparison Performed by Blinded Observers  Federico Biagi, Emanuele Rondonotti,
Enzyme-modified wheat gliadin activates T cells in celiac disease
Volume 9, Issue 2, Pages (August 1998)
Volume 142, Issue 2, Pages e12 (February 2012)
Duodenal expression of a putative stimulator of Fe transport and transferrin receptor in anemia and hemochromatosis  Donatella Barisani, Dario Conte 
Volume 142, Issue 5, Pages e4 (May 2012)
Volume 21, Issue 3, Pages (September 2004)
Volume 151, Issue 4, Pages (October 2016)
Shadi Rashtak, Michael W. Ettore, Henry A. Homburger, Joseph A. Murray 
Volume 115, Issue 1, Pages (July 1998)
Volume 139, Issue 4, Pages e2 (October 2010)
Volume 123, Issue 3, Pages (September 2002)
Volume 128, Issue 2, Pages (February 2005)
Neutrophil Recruitment and Barrier Impairment in Celiac Disease: A Genomic Study  Begoña Diosdado, Harm van Bakel, Eric Strengman, Lude Franke, Erica van.
Volume 21, Issue 3, Pages (September 2004)
Volume 132, Issue 5, Pages (May 2007)
The Intestinal Heme Transporter Revealed
This Month in Gastroenterology
Volume 129, Issue 3, Pages (September 2005)
Volume 118, Issue 3, Pages (March 2000)
Patients With Celiac Disease Are Not Followed Up Adequately
Volume 118, Issue 1, Pages (January 2000)
AGA technical review on celiac sprue
Volume 156, Issue 4, Pages e1 (March 2019)
Covering the Cover Gastroenterology
Volume 114, Issue 6, Pages (June 1998)
Volume 123, Issue 5, Pages (November 2002)
Volume 153, Issue 3, Pages e4 (September 2017)
Mucosal Atrophy in Celiac Disease: Extent of Involvement, Correlation With Clinical Presentation, and Response to Treatment  Joseph A. Murray, Alberto.
Volume 125, Issue 3, Pages (September 2003)
Volume 130, Issue 2, Pages (February 2006)
Accuracy of Testing for Antibodies to Synthetic Gliadin–Related Peptides in Celiac Disease  Emilia Sugai, Horacio Vázquez, Fabio Nachman, María Laura.
Volume 134, Issue 5, Pages (May 2008)
Michelle Maria Pietzak  Gastroenterology 
Volume 119, Issue 2, Pages (August 2000)
Volume 125, Issue 2, Pages (August 2003)
American Gastroenterological Association (AGA) Institute Technical Review on the Diagnosis and Management of Celiac Disease  Alaa Rostom, Joseph A. Murray,
Volume 115, Issue 3, Pages (September 1998)
Presentation transcript:

Volume 125, Issue 3, Pages 696-707 (September 2003) Alterations of the intestinal transport and processing of gliadin peptides in celiac disease  Tamara Matysiak-Budnik, Celine Candalh, Christophe Dugave, Abdelkader Namane, Christophe Cellier, Nadine Cerf-Bensussan, Martine Heyman  Gastroenterology  Volume 125, Issue 3, Pages 696-707 (September 2003) DOI: 10.1016/S0016-5085(03)01049-7

Figure 3 (A) RP-HPLC chromatographic pattern of the native 3H peptide 31–49 before any experiment. (B) Typical elution profile of 3H peptide 31–49 after a 3-hour incubation in the mucosal compartment of duodenal biopsy specimens from controls. (C) Typical elution pattern of 3H metabolites found in the serosal compartment after transport across duodenal biopsy specimens from controls (the same profile was also found in most of the patients with TCD). Gastroenterology 2003 125, 696-707DOI: (10.1016/S0016-5085(03)01049-7)

Figure 5 (A) RP-HPLC chromatographic pattern of the native 3H peptide 57–68 before any experiment. (B) The elution profile after a 3-hour incubation in the mucosal compartment of duodenal biopsy specimens from controls. (C) Typical elution profile of 3H peptide 57–68 metabolites in the serosal compartment after duodenal transport in controls. Gastroenterology 2003 125, 696-707DOI: (10.1016/S0016-5085(03)01049-7)

Figure 8 (A) RP-HPLC chromatographic analysis of the native 3H 33-mer. The same profile was observed after 3 hours of incubation in the mucosal compartment (brush-border membrane) of controls, patients with ACD, or patients with TCD, indicating the absence of degradation. (B–D) Typical elution pattern of 3H 33-mer metabolites observed in the serosal compartment bathing a duodenal biopsy specimen after intestinal transport (3 hours) in controls, patients with ACD, and patients with TCD, respectively. The 33-mer peptide was almost totally degraded in controls and patients with TCD but only partially digested in patients with ACD. Gastroenterology 2003 125, 696-707DOI: (10.1016/S0016-5085(03)01049-7)

Figure 1 (A) Evolution of the electrical resistance of control, ACD, and TCD duodenal biopsy specimens incubated in Ussing chambers in the presence of the gliadin peptides for 3 hours. (B) Initial electrical resistance immediately after mounting the biopsy specimens in the chambers. ∗P < 0.001, significantly different from controls; #P < 0.0003, significantly different from TCD. Gastroenterology 2003 125, 696-707DOI: (10.1016/S0016-5085(03)01049-7)

Figure 2 (A) 3H-equivalent peptide 31–49 fluxes (μg · 3 h−1 · cm2) across control, ACD, and TCD duodenal biopsy specimens mounted in Ussing chambers. ∗P < 0.01, significantly different from controls; #P < 0.002, significantly different from TCD. (B) 3H-equivalent peptide 57–68 fluxes (μg · 3 h−1 · cm2) across duodenal biopsy specimens. (C) 3H-equivalent 33-mer fluxes (μg · 3 h−1 · cm2). Gastroenterology 2003 125, 696-707DOI: (10.1016/S0016-5085(03)01049-7)

Figure 4 (A) Typical RP-HPLC elution profile of the 3H peptide 31–49 after a 3-hour incubation with the mucosal side of a duodenal biopsy specimen from a patient with ACD. (B and C) Typical elution patterns of 3H metabolites found after transport of the 3H peptide 31–49 across duodenal biopsy specimens from patients with ACD. One half of the patients had the type I elution profile, and the remainder had the type II profile. Gastroenterology 2003 125, 696-707DOI: (10.1016/S0016-5085(03)01049-7)

Figure 6 (A) Typical RP-HPLC chromatographic analysis of the 3H peptide 57–68 after 3 hours of contact with the mucosal side of a duodenal biopsy specimen from a patient with ACD (the same profiles were found in patients with TCD). (B) Typical elution pattern of 3H metabolites observed after duodenal transport of the 3H peptide 57–68 in patients with ACD. Gastroenterology 2003 125, 696-707DOI: (10.1016/S0016-5085(03)01049-7)

Figure 7 Comparison of 3H peptide 31–49 and 3H peptide 57–68 metabolites found in the serosal compartment after transport across 2 adjacent duodenal biopsy specimens from the same patient with ACD with subtotal villus atrophy. These 2 biopsy specimens had an electrical resistance of 16.9 and 11.6 ohms · cm2 for peptides 31–49 and 57–68, respectively. Gastroenterology 2003 125, 696-707DOI: (10.1016/S0016-5085(03)01049-7)